Xofigo treatment skin#

In addition, 29% of patients who received the Xofigo combination had fractures, compared with 11% of patients given placebo. In the study, patients given Xofigo with abiraterone acetate (Zytiga) and prednisone/prednisolone died on average 2.6 months earlier than those given placebo with Zytiga and prednisone/prednisolone. The study included patients with no or only mild symptoms, whereas Xofigo is only authorised in patients with symptoms. These restrictions follow a review of data from a study suggesting that patients given Xofigo seemed to be at risk of dying earlier and had more fractures than patients given placebo. Illinois CancerCare serves patients in 12 cities and 12 counties throughout central and western Illinois including Bloomington/Normal, Canton, Carthage, Eureka, Galesburg, Kewanee, Macomb, Ottawa, Pekin, Peoria, Peru and Princeton.European Medicines Agency’s (EMA’s) safety committee, Pharmacovigilance Risk Assessment Committee (PRAC) has recommended at its meeting held from 9 to 12 July 2018 restricting the use of the cancer medicine radium-223 dichloride (Xofigo) to patients who have had two previous treatments for metastatic prostate cancer or who cannot receive other treatments. Illinois CancerCare has 17 physicians, 16 APN’s and more than 230 staff members. The group has been recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program for outpatient hematology-oncology practices that meet the highest national standards for quality cancer care. Illinois CancerCare is central Illinois’ largest network of cancer care specialists with 90-120 open clinical cancer research trials being conducted at any given time. It provides state of the art treatments to its patients against these complex diseases by staying at the leading edge of clinical research.

Illinois CancerCare is one of the largest practices in the state of Illinois that treats patients with cancer and blood diseases. About 239,000 new cases of prostate cancer are diagnosed among American men each year, and nearly 30,000 men die from the disease annually.

Xofigo treatment skin#

Illinois CancerCare has begun to treat a number of prostate cancer patients with Xofigo.Īccording to the American Cancer Society, prostate cancer remains the leading cancer type among men outside of skin cancer, and about one man in every six will develop the illness during his lifetime. This medication is not only a safer option, but also has the potential to prolong the lives of men with prostate cancer.” “Additionally, it was found that patients taking Xofigo lived 3.6 months longer than patients on standard treatment in the clinical trial. A course of treatment is also only 6 injections that are 4 weeks apart, reducing the duration of treatment needed. The most common side effects seen in the clinical trials for Xofigo were nausea, diarrhea, vomiting, and swelling.

Xofigo specifically targets cancer cells in the bone, creating fewer side effects than traditional chemotherapy medications,” states. “This is a fantastic addition in our treatment of advanced-stage prostate cancer. The drug, which was recently approved by the US Food and Drug Administration (FDA), is intended for men whose cancer has spread (metastasized) only to their bones and who have already received treatment to lower testosterone. announced today the introduction of Xofigo® (radium Ra 223 dichloride) in their treatment of certain men with advanced prostate cancer. Treatment specifically targets cancer cells in bone and with fewer side effects Introduces Xofigo in Treatment of Prostate Cancer Introduces Xofigo in Treatment of Prostate Cancer FOR IMMEDIATE RELEASE